Allena Pharmaceuticals — Technical Presentation (November 2019)
22 slides from Allena Pharmaceuticals's technical presentation, Nov 7, 2019
Slide 1: URIROX-1 and Study 206 Topline Results
Exhibit 99.2 URIROX-1 and Study 206 Topline Results November 7, 2019Exhibit 99.2 URIROX-1 and Study 206 Topline Results November 7, 2019
Slide 2: Forward-Looking Statements
Allena Pharmaceuticals, Inc. These slides, and the accompanying presentation, contain forward-looking statements and information. The use of words such as “may,” “might,” “will,” “should,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “project,” “intend,” “future,” “potential,” or “continue
Slide 3: Positive Topline Results from URIROX-1 and Study 206
Positive Topline Results from URIROX-1 and Study 206 Achieved Primary Endpoint: URIROX-2 Positioned for ✓ Highly statistically significant treatment Success difference (p=0.004), and a 23% reduction in 24- - Same UOx primary endpoint hour UOx from baseline on reloxaliase - URIROX-2 sized for long-te
Slide 4: Pioneering Technology in Oral Enzyme Therapeutics
Pioneering Technology in Formulation Oral Enzyme Therapeutics Proprietary Technology development approach Therapeutic Platform Oral Enzyme GI MOA Therapeutic candidates Leverage GI that degrade a specific tract as metabolite “auxiliary kidney” Reloxaliase ALLN-346 Non-absorbed Reduces potential for
Slide 5: Enteric Hyperoxaluria – Disease Overview
Enteric Hyperoxaluria – Disease Overview Gastrointestinal Tract Enteric Hyperoxaluria (EH) Dietary Oxalate Enteric: Pertaining to the intestinal tract Hyper: High or excess Oxal: Oxalate Uria: In the urine Definition: Excess absorption of oxalate in the GI tract due to gastric bypass surgery, inflam
Slide 6: Reloxaliase: First-in-class Therapeutic Candidate for EH
Reloxaliase: First-in-class Therapeutic Candidate for EH Mechanism of Action Target Product Characteristics Oxalate Degradation in the Gastrointestinal Tract Crystalline Oxalate-Specific Enzyme Oxalate Oral Capsule Formulation Taken with Food Non-Absorbed/Non-Systemic Reloxaliase Room Temperature St
Slide 7: Reloxaliase Development Program Addresses the Full Spectrum of Disease
Reloxaliase Development Program Addresses the Full Spectrum of Disease Study Population: Enteric Hyperoxaluria with Enteric Hyperoxaluria CKD and Hyperoxalemia Normal/CKD 1 CKD 2 CKD 3 CKD 4 ESRD • The clinical literature suggests that a ≥ 20% reduction in urine oxalate (UOx) could result in a 25-50
Slide 8: URIROX-1: Evaluate the Safety and Efficacy of Reloxaliase in Patients with Enteric Hyperoxaluria
URIROX-1: Evaluate the Safety and Efficacy of Reloxaliase in Patients with Enteric Hyperoxaluria UOx ≥ 50mg/24h Normal to Stage 3 CKD Reloxaliase Follow up (eGFR ≥ 30) 4 weeks Reloxaliase (7,500 u) or placebo 2 cap with Screening Randomization meal/snack 3 to 5 times per day x 28 days 1:1 N=115 Plac
Slide 9: URIROX-1: Patient Demographics and Baseline Characteristics
URIROX-1: Patient Demographics and Baseline Characteristics Reloxaliase Placebo High Burden of Disease Category / Statistic (N=58) (N=57) Age (years) – Mean (SD) 58.7 (10.09) 58.6 (10.18) Baseline UOx of 89.2 mg/day Gender, n (%) Female 28 (48.3) 27 (47.4) Enteric condition, n (%) Average 11 stone e
Slide 10: URIROX-1 Primary Endpoint: Statistically Significant Reduction of UOx
URIROX-1 Primary Endpoint: Statistically Significant Reduction of UOx URIROX-1 N=115 Reloxaliase Placebo n=58 n=57 0 Achieved primary endpoint Highly statistically significant -5 response verses placebo -10 (P=0.004) -9.7 -15 22.6% reduction in UOx from baseline (LS mean) -20 -14.3% LS mean treatmen
Slide 11: URIROX-1: Summary of Efficacy
URIROX-1: Summary of Efficacy Pre-Specified Sub-Population Overall Population Analysis Bariatric Bariatric Reloxaliase Placebo Reloxaliase Placebo (N=58) (N=57) (N=40) (N=38) PRIMARY ENDPOINT: Percent change in 24h UOx from Baseline during Weeks 1-4 a Comparison in percent change from baseline b LS
Slide 12: Consistent Reloxaliase Treatment Effect Across Phase 2 and Phase 3 Studies
Consistent Reloxaliase Treatment Effect Across Phase 2 and Phase 3 Studies Consistent reduction in UOx of ≥ 20% from baseline in reloxaliase treated patients Highly significant response in pivotal trial compared to placebo (P=0.004) Well tolerated Study 396 (4 Days) Study 713 (4 Weeks) Study 206 (12
Slide 13: Reloxaliase Demonstrates Sustained Reductions in UOx Across Weeks 1-4
Reloxaliase Demonstrates Sustained Reductions in UOx Across Weeks 1-4 URIROX-1 0 Week 1 Week 2 Week 3 Week 4 -5 -10 -15 -20 -25 Reloxaliase Placebo -30 13 Percent Change in UOx (%)Reloxaliase Demonstrates Sustained Reductions in UOx Across Weeks 1-4 URIROX-1 0 Week 1 Week 2 Week 3 Week 4 -5 -10 -15
Slide 14: Reloxaliase Generally Well-Tolerated in Clinical Trials to Date
Reloxaliase Generally Well-Tolerated in Clinical Trials to Date Study 396 Study 649 Study 713 URIROX-1 All Reloxaliase Placebo Reloxaliase Placebo Reloxaliase Placebo (n=16) (n=30) (n=24) (n=32) (n=35) (n=58) (n=57) n (%) n (%) n (%) n (%) n (%) n (%) n (%) 1 TEAE 9 (56.3%) 13 (43.3%) 6 (25.0%) 16 (
Slide 15: Phase 3 Program Design for Accelerated Approval Strategy
Phase 3 Program Design for Accelerated Approval Strategy Week 4: Reloxaliase Follow up 4 weeks N=115 (1:1) Placebo UOx ≥ 50mg/24h, Normal to Stage 3 CKD (eGFR ≥ 30) Week 24: RCT follow-up for Reloxaliase (7,500 u) or placebo 2 BLA submission cap with meal/snack 3-5 x per day minimum of 2 years data
Slide 16: Positive URIROX-1 Results Highlight Potential for Accelerated Approval Submission
Positive URIROX-1 Results Highlight Potential for Accelerated Approval Submission and Provide Insights for URIROX-2 Success Accelerated Approval Submission Post-Approval Confirmatory Endpoints • URIROX-2 shares common UOx primary • UOx decrease in placebo group not expected to be endpoint and key se
Slide 17: Reloxaliase has Potential to Benefit EH Patients With Advanced CKD
Reloxaliase has Potential to Benefit EH Patients With Advanced CKD EH Patients with CKD can Progress to ESRD Patient Presents Progression to Dialysis Kidney Transplant with CKD Stage 5 CKD Procedure t URIROX-2 Study 206 Opportunity * Population Population Delay CKD Progression 1 Delay progression to
Slide 18: Study 206: Robust Reduction in Oxalate Burden in Eight EH Patients with Advanced CKD
Study 206: Reloxaliase Demonstrates Robust Reduction in Oxalate Burden in Eight EH Patients with Advanced CKD Fat Pancreatic Crohn’s Crohn’s Short Bowel RYGB RYGB*/** Crohn’s Disease Malabsorption Insufficiency* Disease** Disease Syndrome CKD Stage 5 CKD Stage 5 CKD Stage 5 CKD 3T CKD Stage 5T CKD S
Slide 19: Reloxaliase: Therapeutic Candidate with Blockbuster Potential
Reloxaliase: Therapeutic Candidate with Blockbuster Potential High Unmet Need in Enteric Hyperoxaluria (EH) Novel Non-absorbed Oral Biologic URIROX-1 Trial Achieves Primary Endpoint with Highly Significant Reduction in UOx (p=0.004) Consistent Results across Phase 2 and 3 Studies Favorable Risk Bene
Slide 20: ALLN-346: Platform Extension Addressing Gout Patients with CKD
ALLN-346: Platform Extension Addressing Significant Opportunity in Gout Patients with Moderate-to-Severe CKD Gout Market is Incompletely Served by Existing Therapies ~375,000 gout patients with moderate to severe CKD who have uncontrolled gout on urate lowering therapy (ULT)* Gout patients with rena
Slide 21: Upcoming Milestones
Upcoming Milestones TARGET MILESTONE STATUS 2Q19 Study 206 Initial Data ✓ 4Q19 URIROX-1 Topline Data ✓ 4Q19 Study 206 Topline Data ✓ 4Q19 ALLN-346 IND Filing On Track 2H20 ALLN-346 Initial Data On Track 2H21 URIROX-2 Topline Data On Track 21Upcoming Milestones TARGET MILESTONE STATUS 2Q19 Study 206
Slide 22: URIROX-1 and Study 206 Topline Results
URIROX-1 and Study 206 Topline Results November 7, 2019URIROX-1 and Study 206 Topline Results November 7, 2019
Allena Pharmaceuticals — Technical Presentation (November 2019) on 6ix